Frederick Pei Li

Frederick Pei Li (May 7, 1940 – June 12, 2015) was a Chinese-American physician.[1][2] He was born in Canton, China (Guangzhou), and raised in New York City, where his parents operated a Chinese restaurant after World War II. His father, Li Hanhun, was a general in World War II (Second Sino-Japanese War) and the chair of Guangdong provincial government during later years of the war.[3]

Frederick Pei Li
Born(1940-05-07)May 7, 1940
Canton, China
DiedJune 12, 2015(2015-06-12) (aged 75)
Alma mater
Known forLi-Fraumeni syndrome
Scientific career
Institutions

He received a B.A. in physics from New York University, an M.D. from the University of Rochester, and M.A. in demography from Georgetown University. In 1967 he joined the Epidemiology Branch of the National Cancer Institute (NCI). He served for 24 years, mostly at the NCI's field station at the Dana-Farber Cancer Institute in Boston. In 1991, he became head of Dana-Farber's Division of Cancer Epidemiology and Control, and retired in 2008.

He was a pioneer researcher of cancer among genetically predisposed families described as Li–Fraumeni syndrome, named after both Dr. Li and his colleague Dr. Joseph Fraumeni.[4] Most recently, Li was Professor of Clinical Cancer Epidemiology at the Harvard T.H. Chan School of Public Health, Professor of Medicine at the Harvard Medical School, and the Harry and Elsa Jiler American Cancer Society Clinical Research Professor. In 1996, Li was appointed by President Bill Clinton to NCI's National Cancer Advisory Board. He died in 2015 of Alzheimer's disease.[5]

Discovery of Li-Fraumeni Syndrome

In 1969, Li with Joseph F. Fraumeni, Jr. identified 24 families with a high risk of cancer throughout generations of family members. Their research and discovery in the abstract of Li and Dr. Fraumeni's paper described their method and results as, "A search of the Cancer Family Registry of the National Cancer Institute revealed 24 kindreds with the syndrome of sarcoma, breast carcinoma, and other neoplasms in young patients. Cancer developed in an autosomal dominant pattern in 151 blood relatives, 119 (79%) of whom were affected before 45 years of age. These young patients had a total of 50 bone and soft tissue sarcomas of diverse histological subtypes and 28 breast cancers. Additional features of the syndrome included an excess of brain tumors (14 cases), leukemia (9 cases), and adrenocortical carcinoma (4 cases) before age 45 years. These neoplasms also accounted for 73% of the multiple primary cancers occurring in 15 family members. Six of these patients had second cancers linked to radiotherapy. The diversity of tumor types in this syndrome suggests pathogenetic mechanisms which differ from hereditary cancers arising in single organs or tissues. The syndrome is presently diagnosed on clinical grounds; laboratory markers are needed to identify high-risk individuals and families and to provide insights into susceptibility mechanisms that may be shared by a wide variety of cancers."[4]

Following these families for twenty years along with the 1990 discovery of inherited (germline) p53 gene mutations led to these mutations as being linked to causing Li-Fraumeni Syndrome.[6] The p53 gene is known as the tumor suppressor gene.[7][8]

Research Interests

Molecular Epidemiology of Hereditary Cancers
In his bio on the Harvard T.H. Chan School of Public Health website, Dr. Li said about his interests and work that "recent data have established that the basic molecular defects in cancer are genetic changes that result in loss of normal cellular control mechanisms. Some of these mutations can be inherited through the germline. I have been studying inherited susceptibility of cancer through affected families. The goal is to identify genes that are involved in cancer development. I was attracted to studies of cancer families because epidemiological studies show that virtually all cancers manifest a tendency to aggregate in families. Close relatives of a cancer patient are at increased risk of that neoplasm, and perhaps other forms of cancer. The excess site-specific cancer risk is exceptionally high for carriers of certain cancer genes, in whom the attack rate can approach 100 percent. In candidate cancer families, the possibility that clustering is on the basis of chance must be excluded through epidemiological studies that establish the presence of an excess cancer risk. Predisposed families are candidates for laboratory studies to identify the inherited susceptibility factors. These investigations have led to the identification and isolation of human cancer genes, the tumor suppressor genes. These cancer genes are among more than 200 single-gene traits associated with the development of cancer. Approximately a dozen inherited susceptibility genes have been definitively identified, and many more are being sought. From studies of retinoblastoma and other rare cancers, important new information was generated about the fundamental biology of cancers that arise in many patients. Isolation of an inherited cancer susceptibility gene provides opportunities for presymptomatic testing of at-risk relatives. However, testing of healthy individuals also raise important issues regarding informed consent, confidentiality and potential for adverse psychological, social and economic effects...My colleagues and I are using families with inherited mutations in the p53 gene, which predisposes to breast cancer and diverse childhood cancers, as a model for developing a genetic testing program."[9]

Awards
  • 1999 Medal of Honor for Clinical Research, American Cancer Society
  • 1998 Harry and Elsa Jiler Clinical Research Professorship, American Cancer Society
  • 1995 Award for Research Excellence in Cancer Epidemiology and Prevention, American Association for Cancer Research/American Cancer Society
  • 1995 Charles S. Mott Prize, General Motors Cancer Research Foundation
gollark: ↓
gollark: A hasquine?
gollark: *84
gollark: Yes.
gollark: `•`?

References
  1. Davies, A.M, et al. (eds.) Imaging of Bone Tumors and Tumor-Like Lesions: Techniques and Applications, p. 683 (2009)
  2. http://www.legacy.com/obituaries/bostonglobe/obituary.aspx?pid=175074195%5B%5D
  3. http://bellodeafuneralhome.tributes.com/obituary/show/Frederick-Pei-Li-102572644%5B%5D
  4. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1988). "A cancer family syndrome in twenty-four kindreds". Cancer Research. 48 (18): 5358–62. PMID 3409256.
  5. Grady, Denise (2015-06-21). "Frederick P. Li, Who Proved a Genetic Cancer Link, Dies at 75". The New York Times.
  6. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA (1990). "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms". Science. 250 (4985): 1233–8. Bibcode:1990Sci...250.1233M. doi:10.1126/science.1978757. PMID 1978757.
  7. P53
  8. The p53 tumor suppressor protein. National Center for Biotechnology Information (US). 1998.
  9. http://www.hsph.harvard.edu/frederick-li/%5B%5D
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.